Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-371-0 | CAS number: 58-25-3
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
There have been reports of increases in severe congenital anomalies in infants whose mothers took chlordiazepoxide and other benzodiazepines (including oxazepam) during pregnancy; there have also been reports claiming no link between benzodiazepine use and fetal abnormalities.
Saito et al. (1984) found increases in fetal toxicity (resorptions, dead fetuses and malformations) in pregnant rats given doses of diazepam or chlordiazepoxide of 100 mg/kg per os during gestational days 7 to 14.
[NTP Technical Report On TheToxicology And Carcinogenesis Studies Of Oxazepam (CAS NO. 604-75-1) IN F344/N Rats October 1998 NTP TR 468 NIH Publication No. 99-3958]
Possible reproductive hazard. Suspected of damaging fertility or the unborn child. Results were mixed in a meta-analysis of studies that tracked the occurrence of major malformations in infants of mothers who used a benzodiazepine in early pregnancy. There have been reports of newborns exhibiting flaccidity, breathing and feeding problems, and hypothermia after maternal use of benzodiazepines in late pregnancy, and withdrawal symptoms, e.g. tremor and irritability, have been seen in newborns exposed to benzodiazepines in utero.
[SDS U. S. Pharmacopeia. Version #: 02 Revision date: 01-19-2015 Issue date: 11-23-2009]
Study in primiparous rats treated during pregnancy and in lactating females rats: apparently teratogenic.
[SDS U. S. Pharmacopeia. Version #: 02 Revision date: 01-19-2015 Issue date: 11-23-2009]
Justification for classification or non-classification
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
